Tarek Sahmoud - 12 Aug 2022 Form 4 Insider Report for Context Therapeutics Inc. (CNTX)

Reporting relationship: Chief Medical Officer
Issuer ticker: CNTX
Reported as of: 12 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Aug 2022, 16:31:15 UTC
Prior SEC filing: 19 Oct 2021
Next SEC filing: 17 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Alex Levit, Attorney-in-Fact

Key filing fact

Tarek Sahmoud filed Form 4 for Context Therapeutics Inc. (CNTX) on 12 Aug 2022.

Key facts

This page summarizes Tarek Sahmoud's Form 4 filing for Context Therapeutics Inc. (CNTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Aug 2022, 16:31.

Change

Previous filing in this sequence was filed on 19 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 12 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $1.96
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable over a two-year period. Fifty percent (50%) of the option vests and becomes exercisable on June 17, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining one year of the two-year period, subject to continued service with the Issuer.